Lindar the Panerunck Reduction Act of 1995, no remove are required to a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10532690		
Filing Date		2005-04-26		
First Named Inventor Kırvin		L. Hodge		
Art Unit		1614		
Examiner Name Nanc		/ L. Zhang		
Attorney Docket Number		18028-PCTUS		

					U.S.I	PATENTS			Remove		
Examiner Initial*				t Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1										
If you wisi	h to a	i did additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLK	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or ,	vhere Rel	or Relevant	T5
	1										С
If you wis	h to a	d additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seria	al, symp	osium,	catalog, etc), o					Τs

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

plication Number		10532690		
ing Date		2005-04-26		
rst Named Inventor Kirvin		L. Hodge		
t Unit		1614		
aminer Name Nancy		L. Zhang		
tornou Docket Number		18028-PCTUS		

	1	Argile (Abst	es, et al., "Journey from cachexia to obesity by TNF", The FASEB . tract)	Journal, 1997, 11(10),	pages 743-751.	
	2		varo, et al., "Tumor necrosis factor alpha produces insulin resistan aB kinase in a p38 MAPK-dependent manner", J. Biol. Chem., 200			
	3		, et al, "Altered insulin response to glucose in weight-losing cancer s 647-650. (Abstract)	patients*, Anticancer	Research, 1994, 14(2B);	
	4		k, "A review of cancer cachexia and abnormal glucose metabolism rican College of Nutrition, 1992, 11(4), pages 445-456. (Abstract)	n in humans with canon	er", Journal of the	
	Wedick, et al., "Insulin resistance precedes weight loss in adults without diabetes: the Rancho Bernardo Study", American Journal of Epidemiology, 2001, 153(12), pages 1199-1205. (Abstract)					
If you wis	h to a	dd add	ditional non-patent literature document citation information p	lease click the Add	button Add	
			EXAMINER SIGNATURE			
Examiner Signature Date Considered						

F

E

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTOP Patent Documents at your USPTO, QUICY on MPEP 901.04. Feither office that issued the document, by the to-better code (WIPO) Standard ST3.3. Froughester plants documents, the reduction of the year of the region of the Eigener standard screed the senial number of the plants document.

Indicated Colument by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here it Eigenhal insignate presentation a statistical.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10532690
Filing Date		2005-04-26
First Named Inventor Kırvin		L. Hodge
Art Unit		1614
Examiner Name Nancy		L. Zhang
Attorney Docket Numb	er	18028-PCTUS

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate selection(s):	
---------------	----------	-------------	----------	---------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Ree set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.	om or the agricult.								
Signature	/Lewis J. Kreisler/	Date (YYYY-MM-DD)	2005-05-07						
Name/Print	Lewis J. Kreisler	Registration Number	38522						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.